司巴沙星与洛美沙星随机对照开放治疗急性细菌性感染81例临床评价

RANDOMIZED CONTROLLED AND OPEN CLINICAL TRIAL ON SPARFLOXACIN COMPARED WITH LOMEFLOXACIN

以进口司巴沙星片为试验药与国产洛美沙星片随机对照治疗急性细菌性感染５９例，司巴沙星开放试验治疗皮肤软组织及肠道感染２２例，共计８１例。两药均每日口服１次，每次２００ｍｇ，疗程７～１４ｄ，随机对照试验中试验药与对照药总有效率分别为９３．３％与８２．８％，细菌清除率分别为９６．７％与９２．９％，药物不良反应发生率分别为６．２５％与６．６７％。开放试验司巴沙星治疗皮肤软组织、肠道感染２２例，临床有效率１００％，细菌清除率１００％，药物不良反应发生率１３．６４％

A randomized controlled clinical trial on sparfloxacin compared with lomefloxacin was conducted. 59 patients with respiratory and urinary tsact infections were randomized to receive either sparfloxacin 200 mg po qd or lomefloxacin 200 mg po qd for 7～14 days. The clinical efficacy rates of sparfloxacin and lomefloxacin were 93.3% and 82.8% respectively. The bacterial clearance rates of the two drugs were 96.7% and 92.9% respectively. The adverse drug reactions of both groups were mild with the rates of 6.25% and 6.67% respectively. An open trial on sparfloxacin for 22 patients with skin and soft tissue infections was conducted. The clinical efficacy rate and the bacterial clearance rate were both 100%. The adverse drug reactions were mild with the rates of 13.64%.